Vitality® GlowCap®, an industry leading smart pill bottle, has been proven to be effective for improving medication adherence

BOSTON – October 25, 2017 NantHealth, Inc. (NASDAQ-GS: NH), a next-generation, evidence-based, personalized healthcare company, today announced that its Vitality Mobile app is now available for download through the Apple and Google Play Stores. When linked with Vitality GlowCap, Vitality Mobile delivers users a comprehensive mobile experience for tracking and improving medication adherence. NantHealth will be showcasing the Vitality medication adherence system at booth 102 at the Connected Health Conference, hosted by the Personal Connected Health Alliance, in Boston at the Seaport World Trade Center from October 25-27, 2017.

Vitality GlowCap is a smart pill bottle that offers automated visual and audible alerts during scheduled medication dosage windows that signal when it is time for the user to take his or her medications. With the new Vitality Mobile app, users can link their mobile device to a Vitality GlowCap to view and track their medication adherence in near-real time. Additionally, users may give their clinicians, care managers and family members access to their adherence information, allowing for buddy reminders and social support.

“Medication nonadherence is a major public health concern that not only affects patient outcomes, but is also costing the overall healthcare industry $100-300 billion a year[1],” said Patrick Soon-Shiong, MD, CEO and founder of NantHealth. “Vitality GlowCap is effective for medication adherence, proven through a peer-reviewed study with Partners Healthcare, Massachusetts General Hospital and Harvard Medical School. Today’s launch of the Vitality Mobile app is another step forward in tackling the issue of medication nonadherence, empowering patients to actively participate in improving their health.”

In a peer-reviewed study conducted with Partners HealthCare – The Center for Connected Health, Massachusetts General Hospital, and Harvard Medical School, audio and visual reminders from the Vitality system were proven to be effective in improving medication adherence. Among study participants, 86 percent of subjects who used Vitality reminders achieved an overall 80 percent medication adherence rate, compared to only 45 percent of subjects meeting that rate without the Vitality reminders.

In addition to providing patients an easy and sustainable way to manage their own medications, the Vitality medication adherence system, comprised of GlowCap and Vitality Mobile, is also useful for hospitals and health systems, pharmacies, accountable care organizations, health insurers, wellness providers and clinical trial sponsors. Specifically, Vitality Mobile can assist pharmaceutical companies, contract research organizations and  hospitals in tracking the frequency that their participants are taking medication – which is required for successful studies.

Cautionary Note Concerning Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding the capabilities and anticipated utility of our GPS Cancer, including predicting patient response and resistance to therapeutics, enabling diagnoses by physicians and accelerating efforts to bring novel combinations of therapeutic agents to cancer patients.


Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results. Factors that may cause future results to differ materially from management’s current expectations include, among other things, that GPS Cancer may not perform as anticipated, that sufficient physicians may not adopt GPS Cancer to assist their diagnoses or that healthcare payers may not provide reimbursement for GPS Cancer as expected. Our business is subject to numerous additional risks and uncertainties, including, among others, risks relating to market acceptance of our products; our ability to successfully launch new products and applications; competition; our sales, marketing and distribution capabilities; our planned sales, marketing, and research and development activities; unanticipated increases in costs or expenses; and risks associated with international operations. Information on these and additional risks, uncertainties, and other information affecting our business and operating results can be found in our existing and future filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements except as may be required by law.

About NantHealth, Inc.

NantHealth, Inc., a member of the NantWorks ecosystem of companies, is a next-generation, evidence-based, personalized healthcare company enabling improved patient outcomes and more effective treatment decisions for critical illnesses. NantHealth’s unique systems-based approach to personalized healthcare applies novel diagnostics tailored to the specific molecular profiles of patient tissues and integrates this molecular data in a clinical setting with large-scale, real-time biometric signal and phenotypic data to track patient outcomes and deliver precision medicine. For nearly a decade, NantHealth has developed an adaptive learning system, which includes its unique software, middleware and hardware systems infrastructure that collects, indexes, analyzes and interprets billions of molecular, clinical, operational and financial data points derived from novel and traditional sources, continuously improves decision-making and further optimizes our clinical pathways and decision algorithms over time. For more information please visit and follow Dr. Soon-Shiong on Twitter @DrPatSoonShiong.


Jen Hodson